2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P08. Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors

P08. Precision Targeted Therapy for RET-driven NSCLC and Emerging Evidence of Acquired Resistance to RET-Specific Tyrosine Kinase Inhibitors

Back to course

Video Transcription

Video Summary

This video discusses the emerging precision medicine approach of RET inhibition in cancer treatment. A case study is presented where a patient achieved durable benefit from RET inhibition for over two years. The importance of repeat profiling to identify actionable resistance mutations to RET inhibition is highlighted, enabling the extension of clinical benefit through combination therapy strategies. The availability of FDA-approved RET-specific inhibitors, selprocatinib and pralsetinib, with high response rates and good tolerability, is also mentioned. The case study demonstrates the value of targeting RET fusion events in adenocarcinomas and emphasizes the need for repeat genomic profiling to guide treatment decisions.

Asset Subtitle

Johnathan Ebben

Meta Tag

Speaker Johnathan Ebben

Topic Targeted Therapies - All Others

Keywords

precision medicine

RET inhibition

cancer treatment

actionable resistance mutations

combination therapy strategies